Spike Protein News and Research

RSS

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Researchers in the United States say the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant – P.1 – that has recently emerged in Brazil shows a worrying level of resistance to neutralization by antibodies.

4 Mar 2021

Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

Researchers found a small molecule that inhibits different virus proteins and significantly reduces infection in cells. Combined with the antiviral remdesivir, its potency increases significantly, suggesting it may be a potential antiviral candidate for the treatment of COVID-19.

4 Mar 2021

Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

The currently approved mRNA vaccines from Moderna and Pfizer-BioNTech help create neutralizing antibodies against the SARS-CoV-2 spike protein. Both companies designed their vaccines to be delivered in two doses. However, given the limited supply of vaccines worldwide, a new modeling study has suggested that vaccinating more people with the first dose and delaying the second could be an alternate route to achieving population immunity that could reduce mortality rates.

4 Mar 2021

Multiple COVID-19 variants of concern have reached Houston, Texas

New research by a team at Houston Methodist Hospital in the United States has modeled the aggressive genomic sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) observed in the United Kingdom to document viral community spread in Houston, Texas.

4 Mar 2021

Novel host-viral-microbiome interactions during COVID-19 may determine outcome

A new preprint on the medRxiv* server discusses how the underlying disease mechanisms are regulated such that the local or mucosal immune response is distinct from the systemic response.

4 Mar 2021

Researchers detect vaccine-induced SARS-CoV-2 antibodies in breast milk

A new paper released on the medRxiv* preprint server describes, for the first time, the detection of antibodies to the virus in human breast milk following the vaccination of lactating mothers. This could guide patients, their healthcare providers, and public health policymakers alike as to the deployment of the vaccines in pregnant and lactating mothers.

4 Mar 2021

SARS-CoV-2 variants do not substantially affect CD4+ and CD8+ T cell responses, study shows

Researchers from California in the United States have conducted a study showing that important adaptive immune responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not affected by four recently emerged variants of the virus.

3 Mar 2021

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.

3 Mar 2021

Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain

Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the miniprotein, LCB1, against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice.

3 Mar 2021

Novel SARS-CoV-2 spike vaccine candidate produces strong neutralizing response in vivo

A new study by researchers at Mahidol University in Bangkok, Thailand, reports a COVID-19 vaccine candidate called HexaPro in producing neutralizing antibodies against the SARS-CoV-2 spike protein in an animal model.

3 Mar 2021

Early antibody response predicts COVID-19 outcome

To address this gap, researchers from the U.S. evaluated the timing of antibody production against SARS-CoV-2 in hospitalized patients. They used a highly sensitive multiplexed bead-based immunoassay that allows for early detection of anti-SARS-CoV-2 antibodies. The study is published on the preprint server medRxiv.

2 Mar 2021

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

Researchers at the New York State Department of Health in the United States have said concerning mutations within the B.1.526 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently become prevalent in New York State warrant further monitoring.

2 Mar 2021

New nanoparticle-delivered COVID-19 vaccine candidate shows efficacy in ferret model

Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models.

2 Mar 2021

Could small synthetic antigen proteins be diagnostic tools for SARS-CoV-2?

Researchers have developed small proteins from sequences in SARS-CoV-2's RBD that bind to ACE2. These were as effective in binding to neutralizing antibodies as larger RBD proteins.

2 Mar 2021

Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccine

Caused by SARS-CoV-2, the coronavirus disease 2019 (COVID-19) pandemic continues to spread across the globe.

From Evonik 2 Mar 2021

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

A new study compares the pathogenicity and infectiousness of one such variant, the VOC 202012/01 (B.1.1.7 lineage) from the United Kingdom, with the globally dominant D614G mutation-carrying strains.

2 Mar 2021

Scientists establish infection models for SARS-CoV-2 UK & South African variants

New research suggests Syrian golden hamsters could be a potentially useful preclinical model for testing vaccine immunity against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.17 and B.1.351 variant.

1 Mar 2021

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

Immunity gained after natural infection from the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is boosted when people take the first Pfizer-BioNTech vaccine, according to a new study led by Iain C. Chapple from the University of Birmingham.

1 Mar 2021

A backbone free energy study of SARS-CoV-2 variants of concern

A recent study by scientist Robert Penner at the Institut des Hautes Études Scientifiques in France utilizes free energy calculations to predict effective antiviral targets that are highly conserved, surface-accessible for interaction, and resistant to mutation.

1 Mar 2021

FDA issues EUA for third COVID-19 vaccine

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Mar 2021

Spike Protein News and Research

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

Multiple COVID-19 variants of concern have reached Houston, Texas

Novel host-viral-microbiome interactions during COVID-19 may determine outcome

Researchers detect vaccine-induced SARS-CoV-2 antibodies in breast milk

SARS-CoV-2 variants do not substantially affect CD4+ and CD8+ T cell responses, study shows

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain

Novel SARS-CoV-2 spike vaccine candidate produces strong neutralizing response in vivo

Early antibody response predicts COVID-19 outcome

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

New nanoparticle-delivered COVID-19 vaccine candidate shows efficacy in ferret model

Could small synthetic antigen proteins be diagnostic tools for SARS-CoV-2?

Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccine

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

Scientists establish infection models for SARS-CoV-2 UK & South African variants

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

A backbone free energy study of SARS-CoV-2 variants of concern

FDA issues EUA for third COVID-19 vaccine

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News